CareFusion (NYSE:CFN) hit a new 52-week high Thursday as it is currently trading at $35.66, above its previous 52-week high of $35.61 with 1.6 million shares traded as of 1:51 p.m. ET. Average volume has been 1.7 million shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- CareFusion (NYSE: CFN) hit a new 52-week high Thursday as it is currently trading at $35.66, above its previous 52-week high of $35.61 with 1.6 million shares traded as of 1:51 p.m. ET. Average volume has been 1.7 million shares over the past 30 days. CareFusion has a market cap of $7.67 billion and is part of the health care sector and health services industry. Shares are up 22.1% year to date as of the close of trading on Wednesday. CareFusion Corporation provides various healthcare products and services in the United States and internationally. It operates in two segments, Medical Systems and Procedural Solutions.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full CareFusion Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.